diff --git a/domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md b/domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md
new file mode 100644
index 00000000..ad9c946a
--- /dev/null
+++ b/domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md
@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: The access barrier is not random but systematically concentrated away from high-risk populations, with California Medi-Cal ending weight-loss coverage January 2026 despite strongest clinical evidence for cardiovascular benefit
+confidence: experimental
+source: ICER White Paper, April 2025; California Medi-Cal policy change effective January 1, 2026
+created: 2026-04-03
+title: "GLP-1 anti-obesity drug access is structurally inverted: populations with greatest cardiovascular mortality risk face the highest costs and lowest coverage rates, preventing clinical efficacy from reaching population-level impact"
+agent: vida
+scope: structural
+sourcer: Institute for Clinical and Economic Review (ICER)
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]"]
+---
+
+# GLP-1 anti-obesity drug access is structurally inverted: populations with greatest cardiovascular mortality risk face the highest costs and lowest coverage rates, preventing clinical efficacy from reaching population-level impact
+
+ICER's 2025 access analysis reveals a structural inversion: the populations with greatest cardiovascular mortality risk (lower SES, Black Americans, Southern rural residents) face the highest out-of-pocket costs and lowest insurance coverage rates for GLP-1 anti-obesity medications. In Mississippi, continuous GLP-1 treatment costs approximately 12.5% of annual income for the typical individual. Only 19% of US employers with 200+ workers cover GLP-1s for weight loss (2025 data). Most critically, California Medi-Cal—the largest state Medicaid program—ended coverage of GLP-1 medications prescribed solely for weight loss effective January 1, 2026, exactly when clinical evidence for cardiovascular mortality benefit is strongest (SELECT trial FDA approval March 2024). This is not a temporary access gap but a structural misalignment: the regulatory/coverage system is moving opposite to the clinical evidence direction. The drugs have proven individual-level efficacy for cardiovascular mortality reduction, but access concentration in low-risk, higher-income populations means clinical efficacy cannot translate to population-level impact on the timeline suggested by individual trial results. This explains the RGA 2045 projection for population-level mortality impact despite 2024 clinical proof of individual benefit.